Document is current

Article History

Received: 22 January 2026

Accepted: 14 April 2026

First Online: 28 April 2026

Change Date: 3 June 2026

Change Type: Update

Change Details: The given and family names of Nessr Abu Rached were incorrectly structured and have been corrected in the original publication.

Declarations

:

: T.G. has received speakers and/or advisory board honoraria from BMS, Sanofi-Genzyme, MSD, Novartis Pharma, Roche, UCB, Abbvie, Almirall, Janssen, Lilly, Pfizer, Pierre Fabre, Merck-Serono, outside the submitted work. N.A. received funding, travel support and/or personal honoraria for lectures from Novartis Pharma, JanssenCilag GmbH, Recordati Rare Diseases Germany GmbH, UCB Pharma, Almirall Hermal GmbH, Bristol-Myers Squibb (BMS) and Johnson & Johnson that were independent of the work submitted. R.G. has received honoraria for lectures/advisory boards from BMS, MSD, Novartis, Merck Serono, Almirall Hermal, SUN Pharma, Sanofi/Regeneron, Pierre Fabre, Immunocore, Janssen, Incyte and Delcath and has received research funding from Amgen, Merck Serono, SUN Pharma, Sanofi/Regeneron, Almirall Hermal, Kyowa Kirin, and Recordati as well as congress participation supported by SUN Pharma and Pierre Fabre, all outside of the submitted work. J.C.B is receiving speaker’s bureau honoraria from Amgen, Incyte Merck-Serono and Regeneron is a paid consultant/advisory board member for Merck-Serono, Incyte, 4SC and Regeneron. His group receives research grants from Regeneron, Merck Serono, and Alcedis. L.S. has received speakers and/or advisory board honoraria from UCB, BMS, Sun-Pharma, MSD, and Novartis. The other authors report no conflicts or competing interests.

: This study was conducted according to the declaration of Helsinki and followed a protocol approved by the institutional ethics review board of the Ruhr-University Bochum (#16–5985).